A detailed history of J.Safra Asset Management Corp transactions in Nuvalent, Inc. stock. As of the latest transaction made, J.Safra Asset Management Corp holds 7 shares of NUVL stock, worth $613. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7
Holding current value
$613
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$67.44 - $112.17 $472 - $785
7 New
7 $0

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.77B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track J.Safra Asset Management Corp Portfolio

Follow J.Safra Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J.Safra Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on J.Safra Asset Management Corp with notifications on news.